STAT+: Abridge inks deals with Nvidia and Lilly

- STAT+: Abridge’s new Nvidia and Lilly deals signal a shift from generic AI to clinical precision. As Rao notes, standard models lack the domain expertise for complex medical workflows. This isn’t just billing automation; it’s about building foundation models that understand the nuance of patient-doctor interactions. For the biotech desk, this is a critical infrastructure update. The integration of specialized AI into pharma and hardware ecosystems suggests a maturing market where accuracy outweighs speed. No panic here, just the steady hum of diagnostic evolution. Friends! The future of health-tech is being coded in real-time.